title: Treatment of inherited protein C deficiency by replacement therapy with the French purified plasma-derived protein C concentrate (PROTEXEL).
abstract: OBJECTIVE
  A multicentre retrospective study was performed to assess the efficacy/safety of a French purified plasma-derived protein C (PC) concentrate in inherited PC deficiency.
  
  
  METHODS
  Nine patients were enrolled, five children aged < 5 weeks, among whom four with a severe deficiency were homozygous, and four patients < 37 years with PC levels ranging 14-25%, including one compound heterozygous.
  
  
  RESULTS
  Thirty replacement therapy courses were recorded with mean PC dosages ranging between 24-90 IU/kg/day for prophylactic courses and 51-209 IU/kg/day for treatment courses. Recoveries varied between 0.8 and 1.12% IU/kg in preventive situations and between 1.09 and 1.91% IU/kg for treatment courses; 23 treatment courses were performed in patients aged 1 day to 18 years, 19 out of 23 treatments resulted in complete recovery with no sequelae. Treatment efficacy was difficult to assess in four out of 23 cases because the thrombotic event was not confirmed in one case and due to late treatment initiation in the three other cases. Seven prophylactic treatments were used either in association of vitamin K antagonists or to prevent thrombotic events due to vitamin K antagonist introduction or withdrawal. The safety assessed during 914 infusions was excellent. No abnormal bleeding was reported, including with high doses, during surgery, with heparin therapy.
  
  
  CONCLUSIONS
  Replacement therapy with this French PC concentrate is safe and effective in patients with inherited PC deficiency.
authors.affiliation: Bicêtre Hospital, Assistance Publique-Hopitaux de Paris, Paris XI University, Le Kremlin Bicêtre, France. marie.dreyfus@bct.aphp.fr
authors.forename: M
authors.initials: M
authors.lastname: Dreyfus
authors.forename: A
authors.initials: A
authors.lastname: Ladouzi
authors.forename: H
authors.initials: H
authors.lastname: Chambost
authors.forename: Y
authors.initials: Y
authors.lastname: Gruel
authors.forename: B
authors.initials: B
authors.lastname: Tardy
authors.forename: P
authors.initials: P
authors.lastname: Ffrench
authors.forename: F
authors.initials: F
authors.lastname: Bridey
authors.forename: Z
authors.initials: Z
authors.lastname: Tellier
mesh_terms: D000293:Adolescent; D000328:Adult; D016913:Blood Component Transfusion / Q000379:methods*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005602:France; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D011486:Protein C / Q000009:adverse effects*; D020151:Protein C Deficiency / Q000628:therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D011486:Protein C